6-K - TLX - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒	Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On April 14, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited (the “Company”) filed announcements with the Australian Securities Exchange titled “Telix Refinances Convertible Bonds,” a copy of which is attached to this Form 6-K as Exhibit 99.1 and “Investor Presentation,” a copy of which is attached to this Form 6-K as Exhibit 99.2.

99.1	Press release – April 14, 2026
99.2	Presentation – April 14, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: April 14, 2026	By:	/s/ Christian Krautkramer
		Name: Christian Krautkramer
		Title: Group General Counsel

Exhibit 99.1

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia
ASX ANNOUNCEMENT

Telix Refinances Convertible Bonds

Melbourne (Australia) and Indianapolis, IN (U.S.) – April 14, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix”) today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer”), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. (the “Offering”). The convertible notes, also referred to as “convertible bonds” (“Convertible Bonds”), are convertible into fully paid ordinary shares in Telix (“Ordinary Shares”).

Managing Director and Group CEO, Dr. Christian Behrenbruch, said: “The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.”

The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix’s current share price.

After deduction of commissions, professional fees and other administrative expenses, it is intended that the net proceeds will be used to repurchase the existing convertible bonds due 2029 (“Existing Convertible Bonds”). Any funds raised above that required for the repurchase of the Existing Convertible Bonds will be applied to general corporate purposes.

Convertible Bonds Offering

•	It is intended that the Convertible Bonds will be listed on the Official List of Singapore Exchange Securities Trading Limited (“SGX-ST”)
•	The Offering is being marketed to eligible investors with the final terms of the Convertible Bonds to be determined via a bookbuild process expected to be completed prior to market open on Wednesday, 15 April 2026
---	---
•	Concurrent with the Offering, a delta placement of Ordinary Shares will be executed to facilitate hedging activity by investors in relation to the Convertible Bonds. The clearing price per Ordinary Share under the delta placement will be<br> used as the reference share price for the Convertible Bonds
---	---
•	More details on the key terms of the Convertible Bonds are provided in the table below
---	---

Stock Borrow Facility

To assist the implementation of the Convertible Bonds Offering, Elk River Holdings Pty Ltd as the trustee for The Behrenbruch Family Trust^1^ (“Stock Lender”) intends to enter into a stock lending agreement with an affiliate of J.P. Morgan (“Stock Borrower”) pursuant to which the Stock Lender will lend a certain number of Ordinary Shares to the Stock Borrower, and the Stock Borrower will be required to return the borrowed Ordinary Shares to the Stock Lender pursuant to the terms of the agreement (“Stock Borrow Facility”).

^1^ Dr Behrenbruch holds an indirect interest.

Page 1

Concurrent Repurchase

Additionally, Telix is conducting a reverse bookbuilding process to receive indications of interest from holders of the Existing Convertible Bonds on a repurchase of the outstanding Existing Convertible Bonds (“Concurrent Repurchase”). The number of Existing Convertible Bonds to be repurchased and the purchase price will be determined by the reverse bookbuilding process.

Adviser

J.P. Morgan Securities plc (“J.P. Morgan”) is Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.

Key terms of the Convertible Bonds

Issuer	Telix Pharmaceuticals (Investments) Inc.
Guarantors	Telix Pharmaceuticals Limited and Telix Pharmaceuticals (US) Inc.
Expected Issue Size	US$550 million
Ranking	Direct, unconditional, unsubordinated and unsecured obligations of the Issuer and Guarantors
Maturity Date	5 years
Investor Put Option	At the end of year 3
Coupon / Yield	1.50 – 1.75%
Conversion Premium	35.0 – 37.5%
Reference Share Price	The clearing price of the Delta Placement – see below
Delta Placement	J.P. Morgan will run a bookbuilding process to facilitate some or all of the hedging activity that may be executed by investors in the Convertible Bonds<br><br> <br><br><br> <br>The clearing price of the Delta Placement will be used as the reference share price to determine the initial conversion price of the Convertible Bonds<br><br> <br><br><br> <br>The manner of conducting the Delta Placement will be determined by J.P. Morgan in consultation with Telix
Conversion Price<br><br> <br>Adjustment	Standard anti-dilutive adjustments including conversion price adjustment for all dividends paid by Telix
Listing	SGX-ST
Selling Restrictions	Reg S (Cat 2) only

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Page 2

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)<br><br> <br>Ms. Kyahn Williamson<br><br> <br>SVP Investor Relations and<br><br> Corporate Communications<br><br> <br>[email protected]	Telix Investor Relations (Australia)<br><br> <br>Ms. Charlene Jaw<br><br> <br>Associate Director Investor<br><br> Relations<br><br> <br>[email protected]	Telix Investor Relations (U.S.)<br><br> <br>Ms. Annie Kasparian<br><br> <br>Director Investor Relations and<br><br> <br>Corporate Communications<br><br> <br>[email protected]

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Neither this announcement nor any copy hereof may be taken into or distributed in the United States.

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an “offshore transaction” as defined in, and in reliance on Regulation S under the Securities Act.

Nothing in this announcement or anything attached to it shall form the basis of any contract or commitment.

Page 3

The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted.

This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

Page 4

Exhibit 99.2

Post- treatment Pre- treatment Investor presentation April 14, 2026 ASX: TLX | NASDAQ: TLX 18F-FET scan published in EJNMMI showing a patient with recurrent glioblastoma (GBM) who experienced a near-complete response following treatment with TLX101-Tx (Iodofalan (¹³¹I), Telix's investigational LAT1-targeted therapy. Patient representative scans, individual results may vary.

You should read this presentation together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this presentation. This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Neither this presentation nor any copy hereof may be taken into or distributed in the United States. The information contained in this presentation is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an “offshore transaction” as defined in, and in reliance on Regulation S under the Securities Act. Nothing in this presentation or anything attached to it shall form the basis of any contract or commitment. The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted. All trademarks and trade names referenced in this presentation are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026 Telix Pharmaceuticals Limited. All rights reserved. Forward looking statements 2

Five pillars underpinning our global leadership in radiopharma 3 High value therapeutics pipeline Vertically integrated manufacturing and supply chain Specialist commercial organization Integrated Theranostic Approach See It. Treat It. R&D platform for new molecular entities Precision Medicine portfolio

Our performance in 20251 4 Strong top-line growth, underlying profitability and cash generation Group revenue $804M up 56% YoY, meeting increased guidance Precision Medicine revenue up 22% YoY to $622M RLS Radiopharmacies adds diversified revenue stream – $170M reported revenue2 Group EBITDA3 $40M, positive cash balance of $142M Pipeline: Four assets in pivotal / Ph3 trials4 Enabling investments that will drive value creation Over $500M investment across R&D, commercial infrastructure and strategic investments has delivered: Commercial: Increased market share driven by our multi-product strategy5 Infrastructure and global supply chain Platform for continued growth High-value clinical research Enhancing our commercial offering All figures throughout presentation provided in USD. Since acquisition close as of January 28, 2025. Earnings before interest, tax, depreciation and amortization. ProstACT Global, NCT06520345; IPAX BrIGHT, NCT07100730; LUTEON, NCT07197580; BiPASS, NCT07052214. Gozellix currently only approved and available in the U.S.

Q1 2026: Group revenue of US$230M, up 11% QoQ Two-product strategy drives strong sequential growth in Q1 2026 Precision Medicine Group Revenue (unaudited) US$M Telix ASX disclosure April 7, 2026. Revenue is provided on an unaudited basis. 5 TMS +11% QoQ Therapeutics 186 204 206 208 230 1

Pathway to launch new Precision Medicine products Pixclara®1 (TLX101-Px, Floretyrosine F 18 or 18F-FET): PDUFA2 goal date of September 11, 20263 Pixlumi®1 (TLX101-Px): European MAA4 submitted Illuccix® (TLX591-Px) New Drug Application accepted in China Therapeutic pipeline advancement ProstACT Global Phase 3 Study of TLX591-Tx in prostate cancer: Part 1 objectives achieved, acceptable safety and tolerability5 Two additional pivotal therapy trials recruiting: IPAX BrIGHT (TLX101-Tx, brain) first patient enrolled, LUTEON (TLX250-Tx, kidney) open for recruitment Strategic collaboration with Regeneron Focused on next-generation therapies, endorsement of Telix’s radiopharma development and manufacturing platform6 Delivering on targeted milestones in early 2026 Demonstrating continued commercial momentum and pipeline advancement 6 Brand name subject to final regulatory approval. Prescription Drug User Fee Act. Telix ASX disclosure April 10, 2026. Marketing Authorization Application. Telix ASX disclosure March 10, 2026. Telix ASX disclosure April 13, 2026.

Precision Medicine portfolio

Precision Medicine near-term growth strategy PSMA portfolio provides platform for growth, potential upside from new product launches Successful Type A meetings completed to align with FDA on key resubmission items ZIRCON-X study showed TLX250-Px imaging has meaningful impact on clinical decisions4 Commercially available in 22 countries1 Pursuing further geographic expansion in China (NDA accepted)2 and Japan (Phase 3 study dosing patients)3 MAA filed for TLX101-Px in Europe and NDA accepted by U.S. FDA, assigned PDUFA goal date September 11, 20265 In a survey of 100 physicians (U.S.), ~70% indicated they are ready to prescribe Pixclara upon FDA approval6 Successful launch (U.S.) BiPASS™, Phase 3 study launched and recruiting rapidly – will support significant market expansion for Illuccix and Gozellix Austria, Czech Republic, Italy, Slovakia, Switzerland, UK, France, Germany, Spain, Portugal, Belgium, Luxembourg, Netherlands, Denmark, Sweden, Finland, Norway, Australia, New Zealand, Brazil, U.S. and Canada. Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) accepted the filing of a NDA, Telix ASX disclosure January 20, 2026. Telix ASX disclosure January 26, 2026. Telix media release November 20, 2025. Telix ASX release April 10, 2026. Shoreline Research, Awareness trial and utilization report, Jan, 2026 Brand names subject to final regulatory approval. Regulatory submission focus on Pixclara and Zircaix in the U.S. to pave way for future launches 7 7 8

Precision medicine: Five-year outlook Building on the current commercial portfolio with BiPASS, Zircaix and Pixclara1 $5.2B $3.6B $2.4B 20% CAGR 30% CAGR 40% CAGR ~$1B (2026) Growth potential Not intended as a forecast or guidance, subject to change due to market conditions and regulatory approvals. Brand names subject to final regulatory approval. 9 1 1

Therapeutics portfolio

Therapeutics pipeline: Late-stage and “next-generation” assets 11 Building a leadership position in urologic and neurologic oncology PSMA: Prostate-specific membrane antigen. CAIX: Carbonic anhydrase IX. LAT1: L-Type amino acid transporter 1. CD66: Cluster of differentiation 66. PDGFRα: Platelet-derived growth factor receptor alpha. mAb: Monoclonal antibody. SM: Small molecule. FAP: Fibroblast activation protein.

12 Potential $32B market opportunity Datamonitor Cancer Patient-Based Forecast and Management Internal Estimates. Prostate-specific membrane antigen. Datamonitor Renal Cell Carcinoma patient-based forecast model and Management Internal Estimates. Datamonitor Glioblastoma patient-based forecast model, and Management Internal Estimates. Leptomeningeal disease (Brain): Nguyen, A.; Nguyen, A.;Dada, O.T.; Desai, P.D.; Ricci, J.C.;Godbole, N.B.; Pierre, K.;Lucke-Wold, B. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic, and Therapeutic Landscape. Curr. Oncol. 2023. Datamonitor Bladder Cancer 2024. Lowery, Caitlin D., et al. "Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors." Clinical Cancer Research, vol. 24, no. 4, Feb. 2018, pp. 847-857. American Association for Cancer Research. Estimates updated Dec, 2025. U.S. oncology market potential by disease area ~15 ~8 ~5 Prostate (PSMA)1 Kidney2 Brain3 Bladder4 Musculoskeletal5 Precision Medicine Therapeutics Total market opportunity $B ~1 ~1 Long-term growth potential across our Precision Medicine and Therapeutics pipeline Total market opportunity ~$32B

V Late-stage assets with upcoming clinical inflection points TLX591-Tx, first-in-class rADC for mCRPC Part 1 lead in safety, dosimetry, data readout1 – primary objectives met Part 2 (randomized treatment expansion), currently dosing patients (ex-U.S.)2 Phase 2/3 Phase 3 TLX101-Tx, potential first radiotherapy in recurrent GBM Part 1 (dose optimization), enrolling patients3 in Australia and Europe Part 2, primary endpoint: OS ODD in U.S. and Europe IPAX-2: Phase 1 trial, newly diagnosed patients – data in 2026 TLX250-Tx, first-in-class rADC for advanced or metastatic ccRCC Part 1 (dose optimization), open for recruitment in Australia. Primary endpoints: safety, RP3D4 IND and CTA submissions in 2026 (US/EU) Part 2 primary endpoint: mPFS TLX090-Tx, novel treatment for bone pain in patients with osteoblastic lesions Part 1 (dose escalation), currently dosing patients (U.S.) Primary endpoints: safety, dosimetry5 Part 2 (dose selection). Primary endpoint: optimal dose (safety, pain score) Phase 3 Phase 1 Phase 2/3 Phase 2/3 rADC = radio antibody-drug conjugate, mCRPC = metastatic Castration-Resistant Prostate Cancer, GBM = Glioblastoma, OS = Overall survival, ODD = Orphan drug designation, EAP = Expanded access program, ccRCC = clear cell Renal Cell Carcinoma, RP3D = recommended phase 3 dose, IND = Investigational new drug, CTA = Clinical trial application, mPFS = median progression free survival, SoC = Standard of care. Telix ASX disclosure March 10, 2026. Part 2 is enrolling in Australia, New Zealand, and Canada, and has also received regulatory approval to commence in China, Singapore, South Korea, Türkiye, and the United Kingdom. Japanese regulator Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2. ClinicalTrials.gov ID: NCT07100730. ClinicalTrials.gov ID: NCT05663710. ClinicalTrials.gov ID: NCT07197645. 13

ProstACT Global Phase 3 (Part 1 Lead-in): Key findings Primary and secondary endpoints: Safety and dosimetry Source: ProstACT Global Part 1 data on file. Demonstrates feasibility of integrating TLX591-Tx with contemporary, global standards of care Study objectives met: Confirmed safety, pharmacokinetics, dosimetry across cohorts No new safety signals: Hematologic events transient and manageable Tolerability profile supported by dosimetry and low-grade non-hematologic events Lesion dosimetry indicates no difference in absorbed dose profile across cohorts No adverse drug-drug interactions observed in TLX591-Tx combinations 14

Strategic collaboration with Regeneron (NASDAQ: REGN) Highly complementary capabilities present a unique opportunity Collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies, including targeted alpha therapies1 Telix to receive US$40 million cash upfront with option to co-fund through commercialization and profit share or earn up to US$2.1 billion in development and commercial milestone payments plus low double-digit royalties Leverages Regeneron’s extensive biologics expertise, with Telix’s radiopharma development platform and global manufacturing and supply chain infrastructure Spans multiple solid tumor targets, from Regeneron’s portfolio of proprietary, clinically validated antibodies with initial focus on lung cancer 15 Telix ASX disclosure April 13, 2026.

2026 strategic priorities

FY 2026 guidance Group revenue US$M Revenue guidance range: $950M to $970M Based on approved products and geographies ~25% growth in Precision Medicine revenue Full year of RLS revenue R&D guidance range: $200M to $240M Increased allocation to therapeutics pipeline R&D investment will be guided by clinical data outcomes and milestones Self-funded through commercial performance 950 - 970 Based on expected global and domestic economic conditions and subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. See Disclaimer for more information. 2022 2023 2024 2025 2026 Continued growth trajectory We will continue reinvesting our earnings to position the Company for long-term growth 17

A catalyst rich 2026 18 BLA = Biologics license application, QIS = QUANTM irradiation system, a cyclotron-based isotope production system. Protocol 177Lu-TLX591-203. Brand name subject to final regulatory approval. Select milestones for Therapeutics candidates Select milestones for Precision Medicine candidates Select milestones for Telix Manufacturing Solutions TLX591-Tx for mCRPC, ProstACT Global Part 1 data readout Part 2 international site expansion, interim analysis1 TLX250-Tx for ccRCC, LUTEON, open for recruitment TLX090-Tx for metastatic bone pain, SOLACE, enrollment completion TLX592-Tx for mCRPC, AlphaPRO, patient dosing TLX102-Tx for recurrent GBM and leptomeningeal disease, trial commencement TLX252-Tx for ccRCC and other CAIX-expressing tumors, trial commencement TLX400-Tx recommencement of clinical activity Pixclara2 NDA resubmission (U.S.) accepted, PDUFA goal date September 11, 2026 Zircaix2 BLA resubmission (U.S.) Illuccix, Gozellix BiPASS™ enrollment completion Illuccix Japan trial, enrollment completion Illuccix China, regulatory approval/launch TLX593-Px (AlFluor™) trial commencement Key RLS sites: commence cyclotron installations EU (Brussels) and Japan (Yokohama) cyclotrons in production 50 ARTMS QIS installations globally TLX101-Tx for recurrent GBM IPAX BrIGHT, first patient enrolled IPAX 2- data readout MTD (Max tolerated dose) Strategic collaboration with Regeneron Pixlumi2 MAA acceptance (Europe)

Q&A

Investor Relations Contacts:Ms. Kyahn Williamson (Global)SVP Investor Relations and Corporate [email protected] Telix Investor Relations (U.S.)  Ms. Annie Kasparian  Director Investor Relations and Corporate Communications  [email protected] Telix Investor Relations (Australia)Ms. Charlene JawAssociate Director Investor [email protected] Illustration of TLX591-Tx Lutetium (177Lu) rosopatamab tetraxetan